Allergy

Article	Citations
Risk factors for severe and critically ill COVID‐19 patients: A review	864
Immune response to SARS‐CoV‐2 and mechanisms of immunopathological changes in COVID‐19	781
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria	382
Distribution of ACE2, CD147, CD26, and other SARS‐CoV‐2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID‐19 risk factors	381
COVID‐19 in a designated infectious diseases hospital outside Hubei Province, China	300
Type 2 immunity in the skin and lungs	290
Eleven faces of coronavirus disease 2019	236
EAACI guidelines: Anaphylaxis (2021 update)	191
The effects of climate change on respiratory allergy and asthma induced by pollen and mold allergens	181
Towards a more precise diagnosis of hypersensitivity to beta‐lactams — an EAACI position paper	169
EAACI Biologicals Guidelines—Recommendations for severe asthma	154
The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update	150
Epithelial cell dysfunction, a major driver of asthma development	146
Epicutaneous sensitization in the development of food allergy: What is the evidence and how can this be prevented?	142
Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID‐19 patients	134
Epithelial barrier hypothesis: Effect of the external exposome on the microbiome and epithelial barriers in allergic disease	130
Immunology of COVID‐19: Mechanisms, clinical outcome, diagnostics, and perspectives—A report of the European Academy of Allergy and Clinical Immunology (EAACI)	125
Clinical characteristics of 182 pediatric COVID‐19 patients with different severities and allergic status	125
Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice	124
Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma	124
The role of peripheral blood eosinophil counts in COVID‐19 patients	113
Abstracts Poster	110
Role of IL‐25, IL‐33, and TSLP in triggering united airway diseases toward type 2 inflammation	110
Is asthma protective against COVID‐19?	108
Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID‐19	105

Allergic reactions to the first COVID‐19 vaccine: A potential role of polyethylene glycol?	100
Spotlight on microRNAs in allergy and asthma	96
Intranasal corticosteroids in allergic rhinitis in COVID‐19 infected patients: An ARIA‐EAACI statement	95
The role of allergen‐specific IgE, IgG and IgA in allergic disease	95
Advances and recent developments in asthma in 2020	94
Is global BCG vaccination‐induced trained immunity relevant to the progression of SARS‐CoV‐2 pandemic?	94
Interleukin‐31: The “itchy” cytokine in inflammation and therapy	92
Antibody dynamics to SARS‐CoV‐2 in asymptomatic COVID‐19 infections	90
Advances and highlights in allergic rhinitis	88
Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches	88
EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID‐19 vaccines	88
Butyrate inhibits human mast cell activation via epigenetic regulation of FcεRI‐mediated signaling	85
Advances and highlights in biomarkers of allergic diseases	84
A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2	84
Asthma and COVID‐19: Is asthma a risk factor for severe outcomes?	83
Allergenic components of the mRNA‐1273 vaccine for COVID‐19: Possible involvement of polyethylene glycol and IgG‐mediated complement activation	81
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines ‐ recommendations on the use of biol	80
Is BCG vaccination affecting the spread and severity of COVID‐19?	80
Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines	77
Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID‐19	75
Advances and novel developments in allergic rhinitis	74
A myoferlin gain‐of‐function variant associates with a new type of hereditary angioedema	73
The global burden of illness of peanut allergy: A comprehensive literature review	72
Handling of allergen immunotherapy in the COVID‐19 pandemic: An ARIA‐EAACI statement	71
EAACI Guidelines on the effective transition of adolescents and young adults with allergy and asthma	71
Advances and highlights in asthma in 2021	71
Regulatory B cells, A to Z	70
Considerations on biologicals for patients with allergic disease in times of the COVID‐19 pandemic: An EAACI statement	70
Distinct characteristics of COVID‐19 patients with initial rRT‐PCR‐positive and rRT‐PCR‐negative results for SARS‐CoV‐2	69
The ingenious mast cell: Contemporary insights into mast cell behavior and function	68
Roles of follicular helper and regulatory T cells in allergic diseases and allergen immunotherapy	68
Butyrate as a bioactive human milk protective component against food allergy	67
Vaccines and allergic reactions: The past, the current COVID‐19 pandemic, and future perspectives	66
Immunological imprint of COVID‐19 on human peripheral blood leukocyte populations	66
Systemic treatments in the management of atopic dermatitis: A systematic review and meta‐analysis	65
Predictors of treatment response in chronic spontaneous urticaria	65
Past, present, and future of allergen immunotherapy vaccines	63
Impact of diet and the bacterial microbiome on the mucous barrier and immune disorders	63
Biologics and airway remodeling in severe asthma	63
Silencing of SARS‐CoV‐2 with modified siRNA‐peptide dendrimer formulation	62
COVID‐19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper	62
Frequency of food allergy in school‐aged children in eight European countries—The EuroPrevall‐iFAAM birth cohort	62
COVID‐19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments	60
Climate change and global health: A call to more research and more action	60
In vitro data suggest that Indian delta variant B.1.617 of SARS‐CoV‐2 escapes neutralization by both receptor affinity and immune evasion	60
Tape strips from early‐onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin	60
Abstracts	60
Advances and novel developments in mechanisms of allergic inflammation	59
Profound dysregulation of T cell homeostasis and function in patients with severe COVID‐19	58
Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma	58

Elastase and exacerbation of neutrophil innate immunity are involved in multi‐visceral manifestations of COVID‐19	58
Global warming, climate change, air pollution and allergies	57
Frequency of food allergy in Europe: An updated systematic review and meta‐analysis	56
Allergen immunotherapy and/or biologicals for IgE‐mediated food allergy: A systematic review and meta‐analysis	56
Anaphylaxis to the first dose of mRNA SARS‐CoV‐2 vaccines: Don't give up on the second dose!	56
Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines	56
Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS‐52 is unaffected by eosinophilic status	54
ARIA‐EAACI statement on severe allergic reactions to COVID‐19 vaccines – An EAACI‐ARIA Position Paper	54
Practice parameters for diagnosing and managing iodinated contrast media hypersensitivity	54
Childhood asthma outcomes during the COVID‐19 pandemic: Findings from the PeARL multi‐national cohort	54
Cold urticaria – What we know and what we do not know	53
SARS‐CoV‐2, COVID‐19, skin and immunology – What do we know so far?	53
Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID‐19	52
Allergies and COVID‐19 vaccines: An ENDA/EAACI Position paper	52
A novel whole blood gene expression signature for asthma, dermatitis, and rhinitis multimorbidity in children and adolescents	51
Adult‐onset eosinophilic airway diseases	50
The global impact of the COVID‐19 pandemic on the management and course of chronic urticaria	50
Phase 2a randomized clinical trial of dupilumab (anti‐IL‐4Rα) for alopecia areata patients	49
ARIA‐EAACI statement on asthma and COVID‐19 (June 2, 2020)	49
Hypersensitivity reactions to chemotherapy: an EAACI Position Paper	49
Risk factors for severe reactions in food allergy: Rapid evidence review with meta‐analysis	49
Past, present, and future of anti‐IgE biologics	48
Baseline type 2 biomarker levels and response to tezepelumab in severe asthma	48
Dexamethasone, pro‐resolving lipid mediators and resolution of inflammation in COVID‐19	47
Role of dietary fiber in promoting immune health—An EAACI position paper	47
IgM and IgA in addition to IgG autoantibodies against FcɛRIα are frequent and associated with disease markers of chronic spontaneous urticaria	47
World Health Organization global air quality guideline recommendations: Executive summary	47
Expanding the allergen repertoire of salmon and catfish	46
COVID‐19 in a patient with severe asthma treated with Omalizumab	46
The maternal diet index in pregnancy is associated with offspring allergic diseases: the Healthy Start study	45
Real‐life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps	45
Allergy and asthma in children and adolescents during the COVID outbreak: What we know and how we could prevent allergy and asthma flares	45
Real‐life assessment of chronic rhinosinusitis patients using mobile technology: The mySinusitisCoach project by EUFOREA	44
Accurate and reproducible diagnosis of peanut allergy using epitope mapping	44
Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID‐ERD: Results from two randomized placebo‐controlled pha	44
Early intervention and prevention of allergic diseases	44
Neutralization of SARS‐CoV‐2 requires antibodies against conformational receptor‐binding domain epitopes	44
ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice	43
The diagnosis and management of allergic reactions in patients sensitized to non‐specific lipid transfer proteins	43
Update on pathomechanisms and treatments in allergic rhinitis	42
Mast cells and complement system: Ancient interactions between components of innate immunity	42
Skin tests in urticaria/angioedema and flushing to Pfizer‐BioNTech SARS‐CoV‐2 vaccine: Limits of intradermal testing	41
Skin pH–dependent Staphylococcus aureus abundance as predictor for increasing atopic dermatitis severity	41
Basophils and their effector molecules in allergic disorders	40
Understanding the challenges faced by adolescents and young adults with allergic conditions: A systematic review	40
Asthma phenotypes, associated comorbidities, and long‐term symptoms in COVID‐19	40
The neighbourhood natural environment is associated with asthma in children: A birth cohort study	39
State‐of‐the‐art in marketed adjuvants and formulations in Allergen Immunotherapy: A position paper of the European Academy of Allergy and Clinical Immunology (EAACI)	38
Open‐label follow‐on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy	38
Single‐cell molecular profiling provides a high‐resolution map of basophil and mast cell development	38
Diagnosing, managing and preventing anaphylaxis: Systematic review	37
Biologicals in atopic disease in pregnancy: An EAACI position paper	37
Allergen immunotherapy: The growing role of observational and randomized trial “Real‐World Evidence”	37
Basophil activation test shows high accuracy in the diagnosis of peanut and tree nut allergy: The Markers of Nut Allergy Study	37
Caspases and therapeutic potential of caspase inhibitors in moderate–severe SARS‐CoV‐2 infection and long COVID	37
Efficacy and safety of dupilumab for moderate‐to‐severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines	37
Breastfeeding promotes early neonatal regulatory T‐cell expansion and immune tolerance of non‐inherited maternal antigens	37
Current perspective on eicosanoids in asthma and allergic diseases: EAACI Task Force consensus report, part I	37
Allergens and their associated small molecule ligands—their dual role in sensitization	36
Peanut‐induced anaphylaxis in children and adolescents: Data from the European Anaphylaxis Registry	36
IgE to epitopes of Ara h 2 enhance the diagnostic accuracy of Ara h 2‐specific IgE	36
APPEAL‐1: A multiple‐country European survey assessing the psychosocial impact of peanut allergy	36
Skin‐infiltrating basophils promote atopic dermatitis‐like inflammation via IL‐4 production in mice	36
Ragweed plants grown under elevated CO2 levels produce pollen which elicit stronger allergic lung inflammation	36
Asthma exacerbations on benralizumab are largely non‐eosinophilic	36
Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes	36
Carbohydrate epitopes currently recognized as targets for IgE antibodies	36
Anti‐KIT monoclonal antibody CDX‐0159 induces profound and durable mast cell suppression in a healthy volunteer study	35
Advances and novel developments in environmental influences on the development of atopic diseases	35
Estrogen receptor‐α signaling increases allergen‐induced IL‐33 release and airway inflammation	35
The role of CD23 in the regulation of allergic responses	35
Nutrient supplementation for prevention of viral respiratory tract infections in healthy subjects: A systematic review and meta‐analysis	34
Emollients in infancy to prevent atopic dermatitis: A systematic review and meta‐analysis	34
Electrical impedance spectroscopy for the characterization of skin barrier in atopic dermatitis	34
Detergent exposure induces epithelial barrier dysfunction and eosinophilic inflammation in the esophagus	34
Eczema herpeticum in atopic dermatitis	34
Mast cell activation is associated with post‐acute COVID‐19 syndrome	34
Benralizumab after sub‐optimal response to mepolizumab in severe eosinophilic asthma	34
Allergen‐specific immunotherapy induces the suppressive secretoglobin 1A1 in cells of the lower airways	34
One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence	33

Humoral immune response of BBIBP COVID‐19 vaccination before and after the booster immunization	33
Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis	33
Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model	33
Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis	33
Glucagon‐like peptide‐1 receptor agonist inhibits aeroallergen‐induced activation of ILC2 and neutrophilic airway inflammation in obese mice	32
Biofilm propensity of Staphylococcus aureus skin isolates is associated with increased atopic dermatitis severity and barrier dysfunction in the MPAACH pediatric cohort	32
Eosinopenia is associated with greater severity in patients with coronavirus disease 2019	32
Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 201	32
CD23 expression on switched memory B cells bridges T‐B cell interaction in allergic rhinitis	32
A scalable and highly immunogenic virus‐like particle‐based vaccine against SARS‐CoV‐2	32
Immunological resilience and biodiversity for prevention of allergic diseases and asthma	32
Recent developments in the immunopathology of COVID‐19	32
The effectiveness of interventions to improve self‐management for adolescents and young adults with allergic conditions: A systematic review	32
Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances	31
Quality of life of children aged 8‐12 years undergoing food allergy oral immunotherapy: Child and parent perspective	31
Comparison of house dust mite sensitization profiles in allergic adults from Canada, Europe, South Africa and USA	31
Autoantibodies in COVID‐19 correlate with antiviral humoral responses and distinct immune signatures	31
Butyrate and propionate restore interleukin 13‐compromised esophageal epithelial barrier function	31
Type 2 inflammation in eosinophilic chronic obstructive pulmonary disease	31
Antibodies in serum of convalescent patients following mild COVID‐19 do not always prevent virus‐receptor binding	31
Food allergy, mechanisms, diagnosis and treatment: Innovation through a multi‐targeted approach	30
COVID‐19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey	30
Management of patients with chronic rhinosinusitis during the COVID‐19 pandemic—An EAACI position paper	30
Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study	30
Infant gut microbiome is enriched with Bifidobacterium longumssp. infantis in Old Order Mennonites with traditional farming lifestyle	30
Severe asthma in adults does not significantly affect the outcome of COVID‐19 disease: Results from the Italian Severe Asthma Registry	29
Early initiation of short‐term emollient use for the prevention of atopic dermatitis in high‐risk infants—The STOP‐AD randomised controlled trial	29
Sweet syndrome induced by SARS‐CoV‐2 Pfizer‐BioNTech mRNA vaccine	29
Biology and dynamics of B cells in the context of IgE‐mediated food allergy	29
Molecular allergology and its impact in specific allergy diagnosis and therapy	29
Accuracy of serological testing for SARS‐CoV‐2 antibodies: First results of a large mixed‐method evaluation study	29
COVID‐19, chronic inflammatory respiratory diseases and eosinophils—Observations from reported clinical case series	29
Human airway epithelial cells express a functional IL‐5 receptor	28
Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions	28
Integration of metagenomics‐metabolomics reveals specific signatures and functions of airway microbiota in mite‐sensitized childhood asthma	28
Lysophosphatidylserine induces eosinophil extracellular trap formation and degranulation: Implications in severe asthma	28
Antibody response after one and two jabs of the BNT162b2 vaccine in nursing home residents: The CONsort‐19 study	28
Allergen immunotherapy for asthma prevention: A systematic review and meta‐analysis of randomized and non‐randomized controlled studies	28
Development and validation of combined symptom‐medication scores for allergic rhinitis*	28
Hypersensitivity pneumonitis: Current concepts in pathogenesis, diagnosis, and treatment	27
Management of patients with atopic dermatitis undergoing systemic therapy during COVID‐19 pandemic in Italy: Data from the DA‐COVID‐19 registry	27
Other excipients than PEG might cause serious hypersensitivity reactions in COVID‐19 vaccines	27
Development and preclinical evaluation of virus‐like particle vaccine against COVID‐19 infection	27
Advanced forecasting of SARS‐CoV‐2‐related deaths in Italy, Germany, Spain, and New York State	27
Experience with polyethylene glycol allergy‐guided risk management for COVID‐19 vaccine anaphylaxis	27
Epithelial barrier dysfunction in ocular allergy	27
Highlights in the advances of chronic rhinosinusitis	27
Prevalence and early‐life risk factors of school‐age allergic multimorbidity: The EuroPrevall‐iFAAM birth cohort	27
T‐cell subsets in the skin and their role in inflammatory skin disorders	27
Definition, aims, and implementation of GA2LEN/HAEi Angioedema Centers of Reference and Excellence	27
Placebo effects in allergen immunotherapy—An EAACI Task Force Position Paper	27
Adverse COVID‐19 outcomes in immune deficiencies: Inequality exists between subclasses	27
Sputum TNF markers are increased in neutrophilic and severe asthma and are reduced by azithromycin treatment	27
Circulating microRNA‐15b‐5p as a biomarker for asthma‐COPD overlap	27
Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial	26
Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study	26
Interleukin‐6: A novel biomarker for monoclonal antibody and chemotherapy‐associated hypersensitivity confirms a cytokine release syndrome phenotype‐endotype association	26
Climate change: A call to action for the United Nations	26
Newly defined allergens in the WHO/IUIS Allergen Nomenclature Database during 01/2019‐03/2021	26
Identification of Pru du 6 as a potential marker allergen for almond allergy	26
Mast cell‐derived serotonin enhances methacholine‐induced airway hyperresponsiveness in house dust mite‐induced experimental asthma	26
Two‐year drug survival of dupilumab in a large cohort of difficult‐to‐treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry	26
Dupilumab reduces inflammation and restores the skin barrier in patients with atopic dermatitis	25
Translation and emerging functions of non‐coding RNAs in inflammation and immunity	25
Sputum macrophage diversity and activation in asthma: Role of severity and inflammatory phenotype	25
SARS‐CoV‐2 receptor ACE2 protein expression in serum is significantly associated with age	25
Prevalence patterns of allergen sensitization by region, gender, age, and season among patients with allergic symptoms in mainland China: A four‐year multicenter study	25
IL‐37 regulates allergic inflammation by counterbalancing pro‐inflammatory IL‐1 and IL‐33	25
Secretoglobins in the big picture of immunoregulation in airway diseases	25
Anti‐KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria	25
Cashew oral immunotherapy for desensitizing cashew‐pistachio allergy (NUT CRACKER study)	25
Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one‐year extension study	25
From DREAM to REALITI‐A and beyond: Mepolizumab for the treatment of eosinophil‐driven diseases	24
Omics technologies in allergy and asthma research: An EAACI position paper	24
Hypersensitivity reactions to biologicals: An EAACI position paper	24
Global implementation of the world health organization's International Classification of Diseases (ICD)‐11: The allergic and hypersensitivity conditions model	24
β‐blockers and ACE inhibitors are not a risk factor for severe systemic sting reactions and adverse events during venom immunotherapy	24
Effect of structural stability on endolysosomal degradation and T‐cell reactivity of major shrimp allergen tropomyosin	24
Exploring novel systemic biomarker approaches in grass‐pollen sublingual immunotherapy using omics	24
Impaired skin barrier and allergic sensitization in early infancy	24
iTRAQ‐based proteomic analysis reveals potential serum biomarkers of allergic and nonallergic asthma	24
Association between asthma and clinical mortality/morbidity in COVID‐19 patients using clinical epidemiologic data from Korean Disease Control and Prevention	24
Distinct expression of SARS‐CoV‐2 receptor ACE2 correlates with endotypes of chronic rhinosinusitis with nasal polyps	24
A bird's eye view on the role of dendritic cells in SARS‐CoV‐2 infection: Perspectives for immune‐based vaccines	24
Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies	24
Retinoic acid‐loading of the major birch pollen allergen Bet v 1 may improve specific allergen immunotherapy: In silico, in vitro and in vivo data in BALB/c mice	23
Abstract	23
In‐vivo diagnostic test allergens in Europe: A call to action and proposal for recovery plan—An EAACI position paper	23
Differentiation of COVID‐19 signs and symptoms from allergic rhinitis and common cold: An ARIA‐EAACI‐GA2LEN consensus	23
Predicting the recurrence of chronic rhinosinusitis with nasal polyps using nasal microbiota	23
The axis of the receptor for advanced glycation endproducts in asthma and allergic airway disease	23
EAACI Biologicals Guidelines—dupilumab for children and adults with moderate‐to‐severe atopic dermatitis	23
Exiting the Anthropocene: Achieving personal and planetary health in the 21st century	23
The value of the basophil activation test in the evaluation of patients reporting allergic reactions to the BNT162b2 mRNA COVID‐19 vaccine	23
Tolerance mechanisms of allergen immunotherapy	23